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Abstract: Psychosis, a break in reality which is manifested as hallucinations, delusions or the
disruption in thought process, is the hallmark of schizophrenia. Despite novel pharmacotherapy
advancements of antipsychotic medications that have resulted in some patients having the ability
to return to social settings and thereby decreasing psychotic symptoms and reducing hospital
admissions, there is still a sub-population of patients who remain symptomatic. Treatment-resistant
schizophrenia is defined as failure of treatment with at least two different antipsychotics with
the proper length of treatment and titration. Clozapine has been heralded as a drug to resolve
the puzzle of treatment-resistant schizophrenia. Clozapine has one side effect that is well known,
being the development of agranulocytosis. However, there is another side effect that can limit
clozapine’s use and can also be life-threatening. Recently, at the end of January 2020, the FDA issued a
communications statement which “[strengthened] an existing warning that constipation caused by the
schizophrenia medicine clozapine can, uncommonly, progress to serious bowel complications.” After
identifying ten cases of constipation from between 2006 to 2016 that progressed to hospitalization,
surgery, and even death, the FDA focused their attention on this often overlooked, common side
effect, especially when considering the strong anticholinergic effects of clozapine. Although patients
are screened by their physicians for agranulocytosis by weekly lab monitoring, constipation is also
a complication that needs to be identified and treated. Much like opioid-induced constipation,
constipation can also be reduced with the use of laxatives and reduction in the co-prescribing of
anticholinergic therapies with clozapine.

Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in

Keywords: clozapine; treatment-resistant schizophrenia; adverse effects; constipation

published maps and institutional affiliations.

1. Introduction
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Swiss psychiatrist Eugen Bleuler was one of the first psychiatrists to use the term
schizophrenia to describe what was once described as Emil Kraepelin as “dementia praecox”. Schizophrenia according to Bleuler would refer to the split of thought, emotion, and
behavior [1]. Today, psychosis, defined as a break in reality manifested as hallucinations,
delusions or disruption in thought process is the hallmark of schizophrenia.
There are certain risk factors, such as a family history of schizophrenia, pregnancy
and birth complications, advanced paternal age, substance abuse of psychoactive or psychotropic drugs during teenage years, and environmental stressors, which increase the risk
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of developing schizophrenia [2]. Twin studies have illustrated the heritability and genetic
component of this disorder and have been crucial in understanding other contributing
factors such as environment [3]. These studies, along with advanced genetic sequencing,
have paved the way to understanding this disorder at the molecular level [4].
In the 1950s, the discovery of the first-generation antipsychotic, chlorpromazine, gave
promise for successful treatment of schizophrenia. Despite this pharmacotherapy advancement that gave some patients the ability to return to social settings and thereby decrease
psychotic symptoms and reduce hospital admissions, there is still a sub-population of patients who remain symptomatic. Treatment-resistant schizophrenia must be distinguished
from incomplete recovery and frequent hospitalizations secondary to patient nonadherence, poor social support, or a history of violence [5]. For years, clozapine was thought
to be an ideal antipsychotic medication related to its efficacy in treating both positive and
negative symptoms, as well as treating treatment-resistant schizophrenia. It has also been
demonstrated to decrease suicidal ideation. However, related to severity and incidence of
adverse effects, it is now used as a backup in patients who have failed at least two other
antipsychotic medications [6]. This review evaluates clozapine, which is considered the
first-line therapy for treatment-resistant schizophrenia. Clozapine has a well-known side
effect of agranulocytosis. However, there is another side effect that can limit clozapine’s
use and can also be life-threatening; this complication is clozapine mediated or modulated
constipation.
1.1. Treatment-Resistant Schizophrenia
Schizophrenia is a complex disorder that leaves many patients debilitated and unable
to function well in society without successful treatment. The majority of patients today respond well to typical or atypical antipsychotics, but approximately one-third of patients are
considered treatment-resistant [7]. It is theorized that schizophrenia can be distinguished
by subtypes, which might link differences in response to treatment with antipsychotics to
certain genetic markers [8].
Treatment-resistant schizophrenia is defined as the persistence of symptoms despite
more than two trials of antipsychotic medications of adequate dose and duration with
documented adherence [9]. Treatment-resistant schizophrenia cannot be explained by
the dopamine hypothesis of schizophrenia [7,10]. The majority of schizophrenia patients
respond to pharmacologic blockade of D2 receptors, but a large population continues to
remain undertreated and symptomatic to the point of disability [10]. Surprisingly, many of
these patients with treatment-resistant schizophrenia will see a response to the atypical
antipsychotic clozapine that has relatively low levels of D2 receptor antagonism [11].
This response may indicate that treatment-resistant schizophrenia symptoms are
driven by non-dopaminergic abnormalities [7]. A 2014 study using positron emission
tomography (PET) scans found that individuals with treatment-resistant schizophrenia
had no increased capacity for dopamine synthesis after antipsychotic treatment compared
to those with disease responsive to antipsychotic treatment [12]. In a separate proton
magnetic resonance spectroscopy study, it was also found that in patients with persistent
psychosis, despite antipsychotic treatment, there were elevated glutamate levels in the
anterior cingulate cortex compared to those who responded to antipsychotic treatment [12].
1.2. Clozapine
Clozapine was discovered in 1959 as the first atypical antipsychotic [13]. Its use
broke the perception that the presence of extrapyramidal symptoms was required for
antipsychotic efficacy and it was deemed “atypical” or “defective” [13]. Imaging and
pharmacological studies have suggested that, unlike typical antipsychotics, clozapine does
not display a high striatal dopamine receptor binding [14]. Rather, it seems to modulate
dopamine, serotonergic, noradrenergic, and glutamatergic receptors [15,16].
Further clinical use continued to reveal that clozapine had excellent efficacy for a wide
range of psychotic symptoms and it gained popularity; however, what also came to light
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was the life-threatening side effect of agranulocytosis [13]. The risk of this side effect drastically decreased the popularity of the drug, but there remained a population of patients
in whom the benefit of a drug capable of treating their symptoms when other treatment
options were exhausted outweighed the risk of this side effect. In a 1988 multicenter trial
based on DSM-III schizophrenics who failed to respond to at least three different neuroleptics and a subsequent six week trial of haloperidol, clozapine efficacy was studied against
chlorpromazine [11]. In this double-blind comparison, 30% of clozapine-treated patients
responded to treatment versus 4% of chlorpromazine-treated patients [11]. Clozapine
was re-introduced in 1989 after a successful FDA application, dramatically changing the
management of patients with refractory psychosis [13].
1.3. Mechanism of Action
Clozapine is a tricyclic dibenzodiazepine derivative that works as an antagonist to both
dopamine and serotonin receptors [17]. Additionally, clozapine also works antagonistically
at adrenergic, cholinergic, and histaminergic receptors [17].
Similar to other second-generation antipsychotics, clozapine exhibits a greater ability
to block serotonin 5-HT2A receptors than dopamine D2 receptors [6]. However, unlike some second-generation medications such as risperidone, clozapine weakly inhibits
dopamine binding at D2 receptors and has a ten times greater affinity for the D4 receptors [6,18]. These binding properties of clozapine contribute to a lower incidence of
extrapyramidal symptoms and a reduction of negative symptoms [18].
Furthermore, clozapine weakly interferes with the D1, D3, and D5 receptors, and has a
high affinity for adrenergic, cholinergic, and 5-HT2C serotonergic receptors [17]. Clozapine
has also been noted to affect muscarinic receptors (blocking M1, M2, M3, and M5 receptors,
while stimulating M4 receptors) and histamine receptors [18–20].
It has also been shown in studies to work on the glutamate system. In a study by
Evins et al., patients that were given clozapine had increased serum glutamate and aspartate concentrations, with clinical improvement in the negative psychotic symptoms [21].
Glutamate is an excitatory neurotransmitter and glutamate increase is thought to be the
reason for the improvement in negative symptoms. Another study postulated that levels
of glutamate and brain neurotrophic factors could actually identify clozapine responders,
those who have increased levels of these two proteins, from clozapine non-responders [22].
In animal studies, clozapine’s mechanism of action on the glutamate receptors was seen in
the pre-frontal cortex where it attenuates the increase in extracellular glutamate efflux and
blocks the firing of N-methyl-D-aspartate (NMDA) receptors [23].
1.4. Pharmacodynamics/Pharmacokinetics
Clozapine is a highly protein-bound drug that is metabolized to norclozapine (desmethylclozapine) and other metabolites by the cytochrome P450 enzymes CYP1A2, CYP3A4,
CYP2C19, and also with some effect from the enzymes CYP2C9 and CYP2D6 [6,24]. Each
enzyme is more effective at different clozapine concentrations and has its own set of inducers and inhibitors, which makes plasma level monitoring and dose adjustments crucial in
maintaining the drug’s therapeutic value [24].
Studies investigating the pharmacokinetic parameters of clozapine in patients with
schizophrenia also echo this need for monitoring, as clozapine was shown to have a
“wide interpatient variability” in the time it takes to reach peak plasma concentrations
(1.1 to 3.6 h), elimination half-life (9.1 to 17.4 h), clearance (8.7 to 53.3 L/h), and volume
of distribution (1.6 to 7.3 L/kg) [25]. Moreover, clozapine exhibits a dose- and timedependent effect on lowering the seizure threshold, and when compared to first-generation
medications, it has a minimal or transient impact on increasing serum prolactin levels [25,26].
2. Clozapine Side Effects and Black Box Warnings
Antipsychotics are associated with a number of side effects, ranging from mild symptoms such as weight gain and drooling to severe effects such as tardive dyskinesia and
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seizures [27]. The side effects of clozapine included common ones such as sedation, hypersalivation, tachycardia, hypo- and hypertension, weight gain, constipation, incontinence,
hepatic effects, and neuromuscular effects [27,28]. A notable exception to clozapine’s list
of adverse effects is extrapyramidal side effects, which are minimal in clozapine unlike
other antipsychotic medications [28]. Despite this unique and clinically useful feature of
clozapine, it remains highly underutilized and unnecessarily discontinued due to physician
uncertainty of management and fear of adverse effects [24,29]. Currently, clozapine has
five FDA black box warnings for agranulocytosis, seizures, myocarditis, cardiovascular
and respiratory effects, and increased mortality from dementia-related psychosis in the
elderly [17]. The most concerning of these is agranulocytosis, although this side effect
occurs in about 0.8% to 2% of patients and can be managed through blood monitoring [24].
Similarly, a number of these side effects such as neutropenia, leukocytosis, and tachycardia
have been shown to require clinical monitoring, but not necessarily clozapine discontinuation [29]. Nevertheless, clozapine is contraindicated in certain patients such as those with
myeloproliferative disorders [17].
Recently, at the end of January 2020, the FDA issued a communications statement
which “[strengthened] an existing warning that constipation caused by the schizophrenia
medicine clozapine can, uncommonly, progress to serious bowel complications” [26]. After
identifying ten cases of constipation from between 2006 to 2016 that progressed to hospitalization, surgery, and even death, the FDA felt that attention was needed on this often
overlooked, common side effect, especially when considering the strong anticholinergic
effects of clozapine [26,30]. From the reported deaths, the causes include necrotizing colitis,
intestinal ischemia, intestinal necrosis, and abdominal distention leading to volvulus [26].
The anticholinergic effects of clozapine can result in gastrointestinal dysfunctions
ranging from mild constipation to severe complications such as intestinal obstruction,
fecal impaction, and/or paralytic ileus [17]. However, fatal events are rare and constipation can be treated with adequate hydration, avoidance of the coadministration of
anticholingergics such as antihistamines, tricyclic antidepressants, antimuscarinics, muscle relaxants, medications for overactive bladder/ incontinence, and use of laxatives or
suppositories [17]. Regardless, if a patient presents with distressing gastrointestinal and
constipation complaints, consultation with a gastroenterologist is warranted [17,26]. Additionally, other practices such as avoidance of co-prescribing other anticholinergics or
constipation-inducing medications (i.e., opioids, iron, calcium, and verapamil), and the
use of prophylactic laxatives can help minimize constipation complications [27,28]. Furthermore, critical to prevention and management is patient and caregiver education on
the risks, prevention, and treatment of clozapine-induced constipation and its potentially
serious complications [16]. Prescribers should be aware and looking out for constipation
if patients are also being treated with benztropine or trihexyphenidyl for extrapyramidal
symptoms, since these are antimuscarinic agents which can worsen constipation.
2.1. Clinical Studies: Constipation
2.1.1. Prevalence
Several studies have investigated the side effects of clozapine such as agranulocytosis,
seizures, myocarditis, and other distressing adverse effects [31]. More recently, studies have
been focusing on the troubling side effect of constipation on clozapine patients given that
17% of patients discontinue treatment due to adverse effects [32]. Constipation as a side
effect of clozapine has been overlooked for years with the use of the drug despite its known
anticholinergic effects. Patients taking clozapine have a prevalence of constipation that is
three times higher than those taking other antipsychotic medications [33]. In order to study
the prevalence of constipation in clozapine patients, a group of researchers performed a
retrospective study. The meta-analysis determined that constipation was a common side
effect of clozapine, and showed evidence that the dose of clozapine related to the prevalence
of constipation—doses higher than 300 mg/day were more frequently associated with
constipation [33]. Furthermore, one study found that there was a low correlation between
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antimuscarinic activity and clozapine dose, but a significant correlation came from the
clozapine plasma levels [34]. Patients taking clozapine doses of 300 mg/day or higher had
higher plasma levels of the drug, thus leading to a higher anticholinergic activity [34].
A study that investigated the prevalence of constipation in patients taking clozapine
found a significant trend in the Bristol Stool Form and Constipation Assessment Scale
(an increase in severity of constipation) with the use of clozapine. A positive correlation
was found between the development of constipation with age, duration of treatment, and
duration of illness [35]. The researchers found a higher incidence rate of constipation
in clozapine patients, but this could be related to the fact that constipation was being
directly investigated compared to previous studies that had been done. Further, patients in
this study who received clozapine as a treatment were four times more likely to develop
constipation [35]. Not only was the prevalence in the clozapine group higher than the
control (a group on a different antipsychotic medication), but they also had a higher severity
of constipation. Additionally, the patients with constipation needed pharmacological
intervention related to severity.
Additional research in Japan, where the use of clozapine was delayed related to apprehension of agranulocytosis development, showed that patients treated over a 12-week
period had a highly significant improvement of their baseline Positive and Negative Syndrome Scale (PANSS) total score [36]. More specifically, patients’ PANSS positive, negative,
and general subscale scores improved. During this study, one patient developed ileus,
and, in addition to two other patients that dropped out, they all recovered in three days
after proper treatment. Constipation, along with other adverse effects such as insomnia,
nausea/vomiting, and hypersalivation, were observed in 30% of the participants in this
trial [36]. This is a significant number of participants, which provides sufficient reasoning to
monitor constipation in patients on clozapine as a serious and life-threatening side effect if
not caught early. This study shows the efficacy of the use of clozapine in treatment-resistant
schizophrenia, and the importance of monitoring side effects, especially constipation.
A cohort study, in Iceland, was done on patients diagnosed with schizophrenia and
using clozapine for therapy to determine the prevalence of constipation and development
of ileus in these patients. The results of the study found that there was a higher prevalence
of constipation in schizophrenic patients on clozapine than what had been previously
stated [37]. This discrepancy could be due to the length of study time, detection bias, or differences in diet and lifestyle in other studies that took place. The researchers recommended
that the physicians increase their screening of constipation in patients taking clozapine in
order to take appropriate action to reduce the risk of developing ileus. Monitoring should
also be increased with patients on additional medications that can cause constipation,
such as anticholinergics, opioids, and tricyclic antidepressants [37]. With the patients on
clozapine plus the additionally previously stated drugs that reduce bowel movement, only
half were receiving laxatives, while only 15.6% of those only on clozapine were given
laxatives [37]. This data shows that the underuse of laxatives during clozapine treatment
can lead to constipation, ileus, or discontinuation of the drug [37]. The researchers were
also able to conclude based on their data that the prevalence of ileus is higher than that of
agranulocytosis, which is typically monitored when compared to larger studies [37]. This
further provides evidence that constipation should be on a physician’s radar when treating
a patient with clozapine.
2.1.2. Screening
Gastrointestinal hypomotility was further researched in a cross-sectional study with
patients taking clozapine. The study found that gastrointestinal hypomotility is a highly
significant problem in any patient taking clozapine with no regard to dose, gender, or
treatment duration [38]. With that being said, in a previously mentioned study, a positive
correlation was found between the development of constipation and age, duration of
treatment, and duration of illness [35]. In this study, it was found that patients taking
clozapine had a median colonic transit time of 104.5 h compared to the 23 h of the control
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group [38]. These results confirm that clozapine has a serious effect on gastrointestinal
motility and bowel function. In order to better monitor the development of constipation,
research has been done on different types of screenings for constipation. In one such study,
a means to objectively identify and question whether or not a patient taking clozapine is
affected by constipation was investigated. To develop an accurate and objective screening
for constipation, the researchers decided to compare the sensitivity, specificity, and positive
and negative predictive values of the patient-reported constipation (PRC) method and
screening for Rome criteria—the standard for assessing constipation symptoms. Both the
PRC method and Rome criteria screening were conducted by trained nurses. In order to
determine the accuracy of each screening method, tests were done using a standardized
radiopaque marker and wireless motility capsule to determine if the patient truly suffered
from constipation. The results of the study showed that both screening methods had
low sensitivity and therefore were not helpful in evaluating constipation symptoms [39].
Despite the low sensitivity of the screenings, patients on clozapine should still be monitored
for constipation due to the severity of mortality and morbidity of the clozapine-induced
gastrointestinal hypomobility [39].
2.2. Adjunctive and Alternatives
With the severity of side effects that clozapine can cause, especially constipation, there
have been few studies on the comparison of effectiveness and risk reduction between
clozapine and other drugs, or clozapine with an adjunctive. In one such study, the researchers compared the anticholinergic effects of clozapine and olanzapine. Participants
received stable therapeutic doses of each drug in their respective group in order to monitor
normal hospital use of these drugs. When directly comparing the anticholinergic properties
of the drugs, participants treated with olanzapine scored lower on the adverse effects
items such as constipation, palpitations, and micturition disturbances [40]. Additionally,
the researchers found a statistical trend for the correlation between clozapine dose and
anticholinergic effects, but they did not find any significance with the correlation to the
olanzapine dose [40]. Additionally, when compared to other antipsychotic drugs such as
haloperidol and antiparkinsonians, clozapine has shown significantly higher activity of
antimuscarinic activity, while the others had low [34].
Some patients on clozapine still have remaining symptoms, so further research has
been done to investigate additional drugs that could be added to the treatment to further
decrease symptoms. Orlistat is a weight control medication that has been used successfully
as a laxative for patients with severe constipation. The drug inhibits lipase, which decreases
the amount of fat absorbed and helps with the passing of stool. This drug is a desirable
treatment for patients with mental illness because the drug does not have any central
nervous system side effects. Researchers investigated the use of orlistat as an adjunctive
treatment for schizophrenic patients on clozapine; a 16-week double-blind randomized
controlled trial with treatment group, orlistat 120 mg, and a control placebo was conducted.
The Bristol Stool Chart was used to assess participant’s stool. During treatment, 35% of
patients in the orlistat group shifted from constipated to non-constipated, while there
was no significant change in the placebo group [41]. In the group receiving orlistat, the
prevalence of constipation decreased unlike those in the control group [41]. The second
hypothesis about weight reduction could not be definitively accepted or rejected due to
the possibility of weight reduction being linked to bowel emptying [41]. The results of
this study showed that orlistat is a potential adjunctive for those on clozapine to reduce
constipation. However, in May of 2010, the FDA issued a warning on post-marketing
adverse events regarding the risk of severe liver injury in people taking orlistat [42].
Minocycline has been the drug to show the most viability in testing to reduce additional symptoms in schizophrenic patients [43]. In order to investigate adjunctive minocycline to clozapine, a double-blind, randomized controlled trial was conducted. Throughout
the study, the side effects of minocycline were monitored, and it was found that the patients
in the minocycline group had similar side effects to the placebo group [43]. This warranted
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that the medication was well tolerated by the patients. Headaches and constipation were
found to be less frequent in the group that used minocycline in addition to clozapine when
compared to the control [43]. Although the researchers did not observe gastrointestinal
side effects or weight loss in patients taking minocycline, previous studies have found
these side effects with higher doses of minocycline, as well as drug-induced lupus [43].
Therefore, patients taking minocycline should be monitored closely for the development of
these side effects and treated as necessary. Previous studies were used to determine the
efficacy of minocycline as an adjunct to improve positive and negative cognitive symptoms
in patients taking clozapine. This study did not find those results, but this may be due to
the power of the study. However, they did find that the use of minocycline as an adjunctive showed significantly improved patients’ anxiety/depression, avolition, and working
memory [43], which are considered core deficits in schizophrenics. With the benefits of
improved deficits, previous studies of improved positive and negative symptoms, and the
decrease in headache and constipation, minocycline is another top candidate for adjunct
therapy with clozapine.
All of these studies were limited by their sample size and power of their investigation,
leading to further research needing to be done. With that being said, the preliminary results
of these studies show that that constipation is a major side effect of clozapine treatment and
should be monitored closely. It is recommended by numerous researchers that monitoring
patient constipation and prophylactic treatment with laxatives and high fiber diets should
become part of the common treatment procedure to prevent the development of ileus or
even death in patients taking the drug [33,38,39,41]. Previous studies have shown that the
use of laxatives improves gut mobility time in patients taking clozapine, and is effective
in countering the clozapine-induced gastrointestinal hypomobility [39]. This approach
would be similar to treatment with opioids for opioid-induced constipation. Additionally,
adjunctive drugs can be used with clozapine in order to decrease these adverse effects as well.
3. Conclusions
Schizophrenia is a chronic disease requiring treatment to prevent disability and improve the lives of patients who suffer from this disorder. Antipsychotics are the mainstay
of treatment, however, there is still a subsection of patients that may be seen as treatmentresistant. Clozapine has been seen as a good alternative for those who have failed treatment
with other antipsychotics. This could be due to the fact that clozapine works on not just
the dopamine system like first-generation antipsychotics, and not just the dopamine and
serotonin dopamine system like second-generation antipsychotics. Indeed, clozapine also
works on the glutamate system which could be the reason why it works better for those
who are treatment-resistant; however, it also has anticholinergic properties which makes
constipation a complication. Studies have shown that constipation is not a complication
to be taken lightly, as it can cause an ileus and intestinal blockage leading to rupture and
death. This complication has been shown in studies to be due to gastrointestinal hypomobility. Although patients are screened by their physicians for agranulocytosis by weekly
lab monitoring, constipation is also a complication that needs to be considered. Much like
opioid-induced constipation, this complication can be reduced with the use of laxatives
and reduction in the co-prescribing of anticholinergic therapies with clozapine.
Patients who have schizophrenia depend on the treatment of their psychotic symptoms
to live as normal a life as possible. Both agranulocytosis and constipation are limiting
side effects. The difference is that one is regularly screened for while the other may not be
screened for by clinicians. It is important for clinicians to both recognize and treat/ prevent
constipation, as treatment options may be limited for those who have failed treatment with
other antipsychotics.
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